US 12146139
Oligonucleotide interference treatments of prostate cancer
granted A61PA61P35/00A61P43/00
Quick answer
US patent 12146139 (Oligonucleotide interference treatments of prostate cancer) held by The Board of Regents of the University of Oklahoma expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Oklahoma
- Grant date
- Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61P, A61P35/00, A61P43/00, A61P5/28